Overview

A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial

Status:
Enrolling by invitation
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men with NASH.
Phase:
Phase 2
Details
Lead Sponsor:
Lipocine Inc.